Patient description: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsed/Refractory Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) confirmed by histopathology, preferably in the detection of tumor tissue PD-L1 expression. 2. A recurrent or refractory disease defined as: 1) recurrence of disease after complete remission (CR); or 2) partial remission (PR), disease stabilization (SD), or disease Progress (PD) when the treatment is completed prior to enrollment in the study. 3. Age≥18 years old, both men and women. 4. The ECOG score is 0-2. 5. There is at least one evaluable lesion (maximum diameter>15mm or shortest diameter>10mm). Preferably, PET-CT shows high metabolism of FDG. 6. Have received appropriate first-line and more-line treatment of the corresponding NHL. 7. Liver and kidney function: blood bilirubin≤35μmol/L, AST or ALT is less than 2 times the upper limit of normal value, serum creatinine≤150μmol/L. 8. The thyroid function is normal. 9. Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraception during treatment. 10. Subjects must sign an informed consent form  Age<18 years old； 2. Received ASCT within 90 days prior to the first use of the study drug; 3. Severe allergies, or patients known to be allergic or intolerant of the drug components of the chemotherapy regimen; 4. Active, unrecognized or suspected autoimmune disease, or a history of autoimmune disease within 2 years; 5. Previously exposed to any antibody against PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4 6. Exposure to any study drug within 4 weeks prior to the first use of the study drug 7. Expose to the last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy or arterial embolization) within 3 weeks prior to the first use of the study drug. 8. Have a history of oncology and have received any treatment for this tumor in the past 3 years; 9. Patients during pregnancy and lactation; 10. Accompanied by severe heart disease, including acute myocardial infarction within 6 months, or in accordance with New York Heart Association cardiac function III or IV; 11. A serological test for HIV or active hepatitis C virus is known to be positive; 12. Hepatitis B virus carriers or hepatitis B virus DNA positive untreated patients are known; 13. TB patients active period 14. Other circumstances that the investigator believes are not suitable for inclusion